Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Acute macular neuroretinopathy, Optical coherence tomography, Visual acuity tests
Clinical narrative: Acute macular neuroretinopathy; This literature-non-study case was reported in a literature article and describes the occurrence of ACUTE MACULAR NEURORETINOPATHY (Acute macular neuroretinopathy) in a 21-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.        No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Spikevax), the patient experienced ACUTE MACULAR NEURORETINOPATHY (Acute macular neuroretinopathy) (seriousness criterion medically significant). The patient was treated with BRIMONIDINE at an unspecified dose and frequency and DIFLUPREDNATE at an unspecified dose and frequency. At the time of the report, ACUTE MACULAR NEURORETINOPATHY (Acute macular neuroretinopathy) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Optical coherence tomography: confirmed acute macular neuroretinopathy (AMN). On an unknown date, Visual acuity tests: was 20/100-1 OD and 20/20 OS and Two weeks after treatment, visual acuity was 20/100-2 OD and 20/25-2 OS.     For mRNA-1273 (Spikevax) (Unknown), the reporter considered ACUTE MACULAR NEURORETINOPATHY (Acute macular neuroretinopathy) to be related.    Patient developed bilateral acute-onset paracentral scotomas three days after receiving the second dose of Moderna COVID-19 vaccination. Diagnosis was confirmed after classic findings were demonstrated on near-infrared reflectance imaging and colored fundus photography. Concomitant medications were not reported.  Company Comment: This is a literature non-study case concerning a 21-year-old female patient with no reported medical history, who experienced the unexpected, serious, event of Acute Macular Neuroretinopathy which was medically significant. The patient developed bilateral acute-onset paracentral scotomas three days after receiving the second dose of the mRNA-1273 COVID-19 vaccine. A clinical diagnosis of Acute Macular Neuroretinopathy (AMN) was confirmed after classic findings were demonstrated on near-infrared reflectance imaging, spectral-domain optical coherence tomography, and colored fundus photography. The patient presented with visual acuity of 20/100-1 OD and 20/20 OS. The patient was treated with Brimonidine and Difluprednate, and after a two-week follow-up, the patient's visual acuity was 20/100-2 OD and 20/25-2 OS. No further information on risk factors, co morbidities, clinical course and management of the events was available in the report. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This is a literature non-study case concerning a 21-year-old female patient with no reported medical history, who experienced the unexpected, serious, event of Acute Macular Neuroretinopathy which was medically significant. The patient developed bilateral acute-onset paracentral scotomas three days after receiving the second dose of the mRNA-1273 COVID-19 vaccine. A clinical diagnosis of Acute Macular Neuroretinopathy (AMN) was confirmed after classic findings were demonstrated on near-infrared reflectance imaging, spectral-domain optical coherence tomography, and colored fundus photography. The patient presented with visual acuity of 20/100-1 OD and 20/20 OS. The patient was treated with Brimonidine and Difluprednate, and after a two-week follow-up, the patient's visual acuity was 20/100-2 OD and 20/25-2 OS. No further information on risk factors, co morbidities, clinical course and management of the events was available in the report. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.